Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update

Cue Biopharma, Inc. (NASDAQ:CUE) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,080,000 shares, an increase of 8.0% from the November 30th total of 1,000,000 shares. Based on an average trading volume of 787,600 shares, the short-interest ratio is presently 1.4 days.

Insider Activity

In related news, CEO Daniel R. Passeri purchased 30,000 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was acquired at an average price of $1.03 per share, for a total transaction of $30,900.00. Following the acquisition, the chief executive officer now directly owns 164,578 shares of the company’s stock, valued at $169,515.34. This trade represents a 22.29 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cue Biopharma during the 2nd quarter valued at about $66,000. GSA Capital Partners LLP grew its holdings in Cue Biopharma by 5.1% in the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after purchasing an additional 14,104 shares during the period. Good Life Advisors LLC increased its position in Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares during the last quarter. Sigma Planning Corp raised its stake in Cue Biopharma by 50.9% during the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after purchasing an additional 135,295 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Cue Biopharma by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock valued at $385,000 after purchasing an additional 16,371 shares during the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Cue Biopharma Stock Performance

Shares of CUE opened at $1.06 on Thursday. Cue Biopharma has a 12-month low of $0.45 and a 12-month high of $3.20. The stock has a market cap of $67.15 million, a P/E ratio of -1.18 and a beta of 1.66. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $1.26 and a two-hundred day moving average of $1.01.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.